# Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer

## TL;DR

Experts discussed new clinical trial designs for high-risk non-muscle invasive bladder cancer, focusing on combination therapies.

## Contribution

A multidisciplinary consensus on next-generation clinical trial strategies for non-muscle invasive bladder cancer was developed.

## Key findings

- A consensus on optimal clinical trial designs for high-risk non-muscle invasive bladder cancer was reached.
- Two clinical trial concepts were proposed for implementation in the National Clinical Trials Network.

## Abstract

The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on ‘Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)’ led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.